You are here

AHF Protests High Cost of Stribild, New AIDS Drug

Group asks for transparency in drug pricing (Sept. 6)

The annual wholesale acquisition cost (WAC) of Stribilid is $28,500 per patient.

Michael Weinstein, president of the AHF, said: “After pricing Stribild at the astronomical amount of $28,500 per year, Gilead’s action today will no doubt make the medication more affordable and accessible for hard-hit state AIDS Drug Assistance Programs and the thousands of people who rely on ADAPs for access to the lifesaving antiretroviral AIDS treatments these programs provide.

“However, the price was simply too high to start with, and this cut is not shared widely enough with other struggling programs. We urge Gilead to immediately expand the price concessions on Stribild to Medicaid, Medicare, private insurers and other payers, while also asking that Gilead — and groups like the ADAP Crisis Task Force — greatly increase the transparency on such drug price negotiations. This secrecy leaves us, AIDS patients, medical providers, and others in the dark, something that we believe is totally inappropriate when tax dollars pay for most of these drugs.”

During the past 3 months, AIDS advocates from AHF and other groups spearheaded a campaign urging John C. Martin, CEO of Gilead, not to decimate ADAP and other drug programs by pricing its latest HIV/AIDS drug combination higher than Gilead’s Atripla, currently the most prescribed HIV/AIDS medication.

In a news release on the price concessions, the ADAP Crisis Task Force noted:

“While pleased with the ADAP price of Stribild, the ACTF acknowledges the disappointment and controversy within the larger HIV community about the $28,500 annual WAC price. Setting the price of Stribild above Atripla … may have implications for costs outside of ADAP, including:

  • It sets a higher price level that may be used by other HIV manufacturers introducing new HIV drugs;
  • It may increase costs to the HIV healthcare system in general during a time when healthcare costs are rising rapidly; and
  • It may result in higher out-of-pocket costs for some patients who pay a co-insurance or co-pay based on a percent of the WAC. Gilead’s decision to increase co-pay assistance limits should help mitigate some of these higher out-of-pocket costs for patients.”

For more information, visit the AIDS Healthcare Foundation Web site.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug